Madrigal Pharmaceuticals, Inc. MDGL Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s total liabilities?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total liabilities of $683.87M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s total liabilities changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s total liabilities increased by 139.1% year-over-year, from $285.99M to $683.87M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s total liabilities has grown at a 69.4% compound annual growth rate (CAGR), from $47.03M to $656.9M.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors.
- How do you interpret total liabilities?
- A rising total liability balance relative to equity indicates increasing financial risk and leverage.
- How does total liabilities compare across companies?
- Standardized metric used to calculate the debt-to-asset ratio across all sectors.